Physician profile
Deborah Rice
NPI 1700915832
$4,432.42
in general payments reported to CMS, 2019-2025
44 companies · $653 in 2025
The $653 reported for 2025 was more than what 78% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,217 · 2022: $967 · 2023: $877 · 2024: $719 · 2025: $653.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,248.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,248.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $614.98 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $428.57 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $343.08 | 2021-2025 | Verquvo, Belsomra, Steglatro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $341.43 | 2021-2024 | Jardiance, Synjardy |
| Corcept Therapeutics | $250.42 | 2022-2025 | Korlym |
| Amgen INC. | $196.57 | 2021-2025 | Evenity |
| Esperion Therapeutics, INC. | $185.95 | 2021-2023 | Nexletol |
| Mayne Pharma Commercial LLC | $179.21 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $153.10 | 2021-2024 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $143.90 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $125.91 | 2021-2022 | |
| Gilead Sciences, INC. | $125.00 | 2022 | |
| Glaxosmithkline, LLC. | $124.66 | 2021-2024 | Trelegy Ellipta |
| Pfizer INC. | $102.42 | 2021-2025 | |
| Astellas Pharma US INC | $102.00 | 2023-2025 | Veozah |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Rice listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.